Lechtzin, Noah

Home monitoring of patients with cystic fibrosis to identify and treat acute pulmonary exacerbations. eICE study results

Lechtzin, N., Mayer-Hamblett, N., West, N. E., Allgood, S., Wilhelm, E., Khan, U., Aitken, M. L., Ramsey, B. W., Boyle, M. P., Mogayzel, P. J., et al. (2017) · American Journal of Respiratory and Critical Care Medicine

Cystic Fibrosis Research AdvancesChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 127

An observational study of outcomes and tolerances in patients with cystic fibrosis initiated on lumacaftor/ivacaftor

Jennings, M. T., Dezube, R., Paranjape, S., West, N. E., Hong, G., Braun, A., Grant, J., Merlo, C. A., & Lechtzin, N. (2017) · Annals of the American Thoracic Society

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 71

Risk factors for persistent Aspergillus respiratory isolation in cystic fibrosis.

Hong, G., Psoter, K. J., Jennings, M. T., Merlo, C. A., Boyle, M. P., Hadjiliadis, D., Kawut, S. M., & Lechtzin, N. (2018) · Journal of Cystic Fibrosis

Cystic Fibrosis Research AdvancesAntifungal resistance and susceptibility

Cited by 59

Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study

Flume, P. A., Biner, R. F., Downey, D. G., Brown, C., Jain, M., Fischer, R., De Boeck, K., Sawicki, G. S., Chang, P., Paz-Diaz, H., et al. (2021) · The Lancet Respiratory Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 52